与在心房的患者中使用无人机相关的经济影响
Zenobia Dotiwala1, Julian Casciano1, Gary Lebovics1
1Research and Analytics, eMAX Health, Delray Beach, FL, USA.
Journal of medical economics
|January 28, 2025
概括
与其他抗心律失常药物 (AADs) 相比,在心房动 (AF) 患者中使用dronedarone与较低的心血管 (CV) 住院费用有关. 这项研究量化了这些经济效益,显示了心力衰竭住院治疗的显著成本节约.
科学领域:
- 心脏病学 心脏病学
- 卫生经济学 卫生经济学
背景情况:
- 2009年批准的德罗内达龙在心房动 (AF) 患者中证明心血管 (CV) 事件减少.
- 2020年的一项研究表明,在临床实践中,使用无人机的CV住院和死亡率较低,而不是其他抗心律不良药 (AAD).
- 在AF管理中使用无人机的经济影响仍然被低估.
研究的目的:
- 估计与其他AADs相比,用dronedarone治疗的AF患者的CV结果相关的经济成本.
主要方法:
- 利用来自CMS数据库的全国平均医疗保险支付来进行成本估计.
- 雇佣了与诊断相关的分组,以将成本分配给CV结果.
- 在没有CMS数据的情况下,对住院费用进行了文献搜索.
主要成果:
- CV住院的加权平均成本为20508.8美元.
- 对于CV住院住院的每人/年成本是14%低于dronedarone (3679美元) 与其他AAD (4272美元) 相比.
- 与其他ADS ($472) 相比,心力衰竭住院费用在dronedarone (324美元) 下降了31%,低于其他ADS ($472).
结论:
- 与其他AAD相比,在AF患者中使用dronedarone与心血管住院的成本降低有关.
- 观察到的经济效益可能会影响治疗决策和医疗资源分配.
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
924
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
924
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
791
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
791
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
718
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
718
01:25Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396